XLO Xilio: Enterprise Value-to-Revenue Multiple

Public company logo of Xilio Therapeutics Inc (XLO)

The prospects for Xilio Therapeutics, Inc. (XLO) are limited by fierce competition in tumor therapy and potential funding shortages. The shift in the EV/Sales ratio reflects market expectations, with the metric currently standing at -1148.34. Growth potential is based on the GEAR platform, which creates selective cytokines with low toxicity. However, the lack of current sales and rising research expenses hinder the scaling of the business at this stage of development.

Xilio - XLO Company Value to Revenue (period 11/23/2025 - 11/20/2026)

Xilio - analytical breakdowns and key metrics (XLO)

- market price and analyst price targets:
- money and cash flow information:
Initial company analysis:Xilio Therapeutics Inc XLO
Product sample of Xilio Therapeutics Inc

The EV/Sales multiple determines the market value of the business, including net debt relative to sales volume, allowing for an assessment of future growth potential regardless of financial leverage. The valuation trend of Xilio Therapeutics, Inc. (XLO) based on the EV/Sales multiple reflects market expectations for the company's proprietary immune molecule activation platform, where a high revenue premium confirms the uniqueness of the R&D cycle and significant barriers to entry for competitors.

Competitor analysis for Xilio Therapeutics, Inc.

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Company Value to Revenue Ratio CGON (CG Oncology Corp)|Enterprise Value-to-Revenue Ratio UroGen Pharma (URGN)|EV/Sales Multiple Bicara Therapeutics (BCAX)|EV/Sales Multiple PSNL (personalis.com)|Business Value to Revenue ERAS|DCTH: Company Value to Revenue|YmAbs - Enterprise Value-to-Revenue Coefficient|aurabiosciences.com (AURA) - Enterprise Value-to-Revenue Ratio|Candel Therapeutics Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Accuray Inc.|Enterprise Value-to-Revenue Multiple SELLAS Life Sciences Group SLS|EV/Sales Multiple ACTU|CTOR - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple HURA (TuHURA Biosciences, Inc.)|Business Value to Revenue TARA|FATE: Company Value to Revenue|WHWK (aadibio.com) - Company Value to Revenue Ratio|TCRX (TScan Therapeutics, Inc.) - Company Value to Revenue|Enterprise Value-to-Revenue Multiple Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - EV/Sales Multiple|CVM (CEL-SCI Corporation) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple OSTX|EV/Sales Multiple Radiopharm Theranostics Ltd (RADX)|EV/Sales Multiple ARTV (Artiva Biotherapeutics)|EV/Sales Multiple Adlai Nortye Ltd. ANL|Veru Inc - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Tempest Therapeutics TPST|RENB: EV/Sales Multiple|Company Value to Revenue Mural Oncology plc|Enterprise Value-to-Revenue Ratio Kairos Pharma Inc|OKUR: Business Value to Revenue|EV/Sales Multiple GDTC|CRIS (Curis) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio apollomicsinc.com APLM|THAR: Company Value to Revenue Ratio|advanbiomed.com - EV/Sales Multiple|Business Value to Revenue GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Enterprise Value-to-Revenue Ratio|Sunshine Biopharma Inc. (SBFM) - EV/Sales Multiple|XBIO (Xenetic Bio) - EV/Sales Multiple|Salarius Pharmaceuticals Inc (SLRX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PPBT|EV/Sales Multiple American Oncology Network Inc (AONC)|EV/Sales Multiple BGNE (BeiGene Ltd.)|Enterprise Value-to-Revenue Coefficient CKPT (Checkpoint Therapeutics)|ELEV - Enterprise Value-to-Revenue Ratio|ICAD (iCAD Inc.) - Company Value to Revenue Ratio|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio